Table 2. Clinicopathological characteristics and correlation with CA9, CD31, CD68 and CD20 expression.
| Low CA9n (%) | High CA9n (%) | p-value | Low CD31n (%) | High CD31n (%) | p-value | Low CD68n (%) | High CD68n (%) | p-value | Low CD20n (%) | High CD20n (%) | p-value | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age | ||||||||||||
| < median (65 years) | 42 (60%) | 20 (28.6%) | < 0.001 | 30 (42.9%) | 32 (45.7%) | 0.734 | 28 (43.1%) | 34 (44.7%) | 0.843 | 22 (44.0%) | 46 (50.5%) | 0.285 |
| ≥ median | 28 (40%) | 50 (71.4%) | 40 (57.1%) | 38 (54.3%) | 37 (56.9%) | 42 (55.3%) | 28 (56.0%) | 45 (49.5%) | ||||
| Gender | ||||||||||||
| Female | 34 (48.6%) | 34 (48.6%) | 1.000 | 35 (50%) | 33 (47.1%) | 0.735 | 29 (44.6%) | 39 (51.3%) | 0.427 | 22 (44.0%) | 33 (47.1%) | 0.457 |
| Male | 36 (51.4%) | 36 (51.4%) | 35 (50%) | 37 (52.9%) | 36 (55.4%) | 37 (48.4%) | 28(50%) | 37 (52.9%) | ||||
| Tumor site | ||||||||||||
| Head | 55 (78.6%) | 62 (88.6%) | 0.111 | 58 (82.9%) | 59 (84.3%) | 0.820 | 56 (86.2%) | 62 (81.6%) | 0.464 | 43 (86.0%) | 75 (82.4%) | 0.843 |
| Other | 15 (21.4%) | 8 (11.4%) | 12 (17.1%) | 11 (15.7%) | 9 (13.8%) | 14 (18.4%) | 7 (14.0%) | 16 (17.6%) | ||||
| pT-staging | ||||||||||||
| pT1-2 | 42 (60%) | 42 (60%) | 1.000 | 44 (62.9%) | 40 (57.1%) | 0.490 | 43 (66.2%) | 42 (55.3%) | 0.188 | 30 (60.0%) | 55 (60.4%) | 0.959 |
| pT3-4 | 28 (40%) | 28 (40%) | 26 (37.1%) | 30 (42.9%) | 22 (33.8%) | 34 (44.7%) | 20 (40.0%) | 36 (39.6%) | ||||
| pN-staging | ||||||||||||
| pN0 | 17 (24.3%) | 16 (22.9%) | 0.842 | 20 (28.6%) | 13 (18.6%) | 0.163 | 17 (26.2%) | 17 (22.4%) | 0.600 | 14 (28.0%) | 20 (22.0%) | 0.424 |
| pN+ | 53 (75.7%) | 54 (77.1%) | 50 (71.4%) | 57 (81.4%) | 48 (73.8%) | 59 (77.6%) | 36 (72.0%) | 71 (78.0%) | ||||
| Grading | ||||||||||||
| G1 | 5 (7.1%) | 3 (4.3%) | 0.610 | 4 (5.7%) | 4 (5.7%) | 0.856 | 5 (7.1%) | 3 (4.3%) | 0.610 | 4 (6.2%) | 4 (5.3%) | 0.870 |
| G2 | 42 (60%) | 47 (67.1%) | 46 (65.7%) | 43 (61.4%) | 42 (60%) | 47 (67.1%) | 40 (61.5%) | 50 (65.8%) | ||||
| G3 | 23 (35.9%) | 20 (28.6%) | 20 (28.6%) | 23 (32.9%) | 23 (35.9%) | 20 (28.6%) | 21 (32.3%) | 22 (28.9%) | ||||
| Resection margins | ||||||||||||
| R0 | 24 (34.3%) | 28 (40%) | 0.484 | 24 (34.3%) | 28 (40%) | 0.484 | 26 (40.0%) | 27 (35.5%) | 0.585 | 16 (32.0%) | 57 (40.7%) | 0.719 |
| R1 | 46 (65.7%) | 42 (60%) | 46 (65.7%) | 42 (60%) | 39 (60.0%) | 49 (64.5%) | 34 (68.0%) | 54 (59.3%) | ||||
| Type of surgery | ||||||||||||
| Whipples | 46 (65.7%) | 44 (62.9%) | 0.833 | 46 (65.7%) | 44 (62.9%) | 0.494 | 44 (67.7%) | 46 (60.5%) | 0.463 | 37 (74.0%) | 53 (58.2%) | 0.119 |
| Pylorus preserving | 17 (24.3%) | 20 (28.6%) | 16 (22.9%) | 21 (30.0%) | 17 (26.2%) | 21 (27.6%) | 11 (22.0%) | 27 (29.7%) | ||||
| Total pancreatectomy | 7 (10.0%) | 6 (8.6%) | 8 (11.4%) | 5 (7.1%) | 4 (6.2%) | 9 (11.8%) | 2 (4.0%) | 11 (12.1%) | ||||
| PNI | ||||||||||||
| no | 52 (74.3%) | 58 (82.9%) | 0.217 | 59 (84.3%) | 51 (72.9%) | 0.099 | 57 (87.7%) | 54 (71.1%) | 0.016 | 39 (78.0%) | 72 (79.1%) | 0.876 |
| yes | 18 (25.7%) | 12 (17.1%) | 11 (15.7%) | 19 (27.1%) | 8 (22.0%) | 22 (28.9%) | 11 (22.0%) | 19 (20.9%) | ||||
| VI | ||||||||||||
| no | 19 (27.1%) | 31 (44.3%) | 0.034 | 22 (36.8%) | 28 (40%) | 0.290 | 24 (36.9%) | 27 (35.5%) | 0.863 | 18 (36.0%) | 33 (36.3%) | 0.975 |
| yes | 51 (72.9%) | 30 (55.7%) | 48 (68.6%) | 42 (60) | 41 (63.1%) | 49 (64.5%) | 32 (64.0%) | 58 (63.7%) | ||||
| LI | ||||||||||||
| no | 23 (32.9%) | 28 (40%) | 0.380 | 30 (42.9%) | 21 (30%) | 0.114 | 25 (38.5%) | 27 (35.5%) | 0.719 | 16 (32.0%) | 36 (39.6%) | 0.373 |
| yes | 47 (67.1%) | 42 (60%) | 40 (57.1%) | 49 (70%) | 40 (61.5%) | 49 (64.5%) | 34 (68.0%) | 55 (60.4%) | ||||
| Chemotherapy | ||||||||||||
| No | 7 (10%) | 12 (17.1%) | 0.283 | 6 (8.6%) | 13 (18.6%) | 0.541 | 7 (10.8%) | 12 (15.8%) | 0.523 | 6 (12.0%) | 13 (14.3%) | 0.676 |
| 1–2 cycles | 18 (25.7%) | 12 (17.1%) | 15 (21.4%) | 15 (21.4%) | 16 (24.6%) | 14 (18.4%) | 9 (18.0%) | 21 (23.1%) | ||||
| ≥ 3 cycles | 45 (64.3%) | 46 (65.7%) | 49 (70.0%) | 42 (60.0%) | 42 (64.6%) | 50 (65.8%) | 35 (70.0%) | 57 (62.6%) |
Abbreviations: PNI, perineural/neural invasion; VI, vascular invasion; LI, lymphatic invation.